Local Bounti Corporation Form 8-K Summary
Business Context and Reporting Period
Local Bounti Corporation, a Delaware company listed on the NYSE under ticker LOCL, filed a Current Report on Form 8-K regarding an NYSE continued-listing deficiency. The earliest reported event occurred on April 3, 2024; the report was signed and filed on April 5, 2024.
Financial Metrics and Liquidity
- The filing does not provide current-period revenue, profit, cash flow, margins, debt, liquidity, or other operating-performance metrics.
- The NYSE stated that the Company’s average global market capitalization over a consecutive 30-trading-day period was below $50 million and that its last reported stockholders’ equity was also below $50 million.
Material Changes and Listing Status
- On April 3, 2024, the Company received an NYSE notice that it was not in compliance with Rule 802.01B, the Minimum Market Capitalization Standard.
- The notice does not immediately affect the listing or trading of the Company’s common stock, which is expected to continue during the cure period, subject to compliance with other NYSE standards.
- The Company intends to notify the NYSE of its intent to cure the deficiency and submit a compliance plan within 45 days of receiving the notice.
- If accepted, the plan would provide an 18-month Market Capitalization Cure Period. The NYSE will review the plan and conduct quarterly reviews of the Company’s progress.
Outlook, Risks, and Unusual Items
- The Company is considering available measures to regain compliance and plans to pursue actions it believes are in the best interests of the Company and its stockholders.
- The NYSE could initiate suspension and delisting proceedings before the end of the cure period if the plan is not timely submitted, is rejected, or the Company does not make sufficient progress.
- The Company provides no assurance that it will restore compliance or maintain its NYSE listing.
- Forward-looking statements are subject to risks including the Company’s ability to regain compliance within the cure period and continue satisfying NYSE listing standards, as well as risks described in its 2023 Form 10-K.
- A press release dated April 5, 2024, was furnished as Exhibit 99.1 under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act.
Important Facts for Investors to Verify
- The date and outcome of the Company’s required notice to the NYSE regarding its intent to cure the deficiency.
- Whether the NYSE accepts the Company’s compliance plan and the specific actions proposed.
- Progress toward restoring both the required market capitalization and stockholders’ equity levels.
- NYSE quarterly reviews and any subsequent notices concerning suspension, delisting, or continued listing.
- The Company’s latest financial statements, including cash resources, debt obligations, operating losses, and factors affecting stockholders’ equity.